Renalytix AI plc (RENX) - Total Assets
Based on the latest financial reports, Renalytix AI plc (RENX) holds total assets worth GBX11.44 Million GBX (≈ $1.39K USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Renalytix AI plc - Total Assets Trend (2012–2025)
This chart illustrates how Renalytix AI plc's total assets have evolved over time, based on quarterly financial data. Also see RENX market cap for the company's overall valuation and market capitalisation.
Renalytix AI plc - Asset Composition Analysis
Current Asset Composition (June 2025)
Renalytix AI plc's total assets of GBX11.44 Million consist of 95.1% current assets and 4.9% non-current assets. Review RENX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 59.0% |
| Accounts Receivable | GBX600.00K | 9.8% |
| Inventory | GBX200.00K | 3.3% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Renalytix AI plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Renalytix AI plc (RENX) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Renalytix AI plc's current assets represent 95.1% of total assets in 2025, an increase from 26.3% in 2012.
- Cash Position: Cash and equivalents constituted 59.0% of total assets in 2025, up from 5.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 46.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 9.8% of total assets.
Renalytix AI plc Competitors by Total Assets
Key competitors of Renalytix AI plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Singular Health Group Ltd
AU:SHG
|
Australia | AU$12.55 Million |
|
NexgenRX Inc.
V:NXG
|
Canada | CA$39.20 Million |
|
Intrasense
PA:ALINS
|
France | €7.99 Million |
|
Medadvisor Ltd
AU:MDR
|
Australia | AU$39.84 Million |
|
HITIQ Ltd
AU:HIQ
|
Australia | AU$3.28 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$92.19 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
Renalytix AI plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 0.59 | 14.12 |
| Quick Ratio | 2.34 | 0.56 | -3915.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX6.58 Million | GBX-5.67 Million | GBX17.09 Million |
Renalytix AI plc - Advanced Valuation Insights
This section examines the relationship between Renalytix AI plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.06 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -23.5% |
| Total Assets | GBX6.10 Million |
| Market Capitalization | $332.33K USD |
Valuation Analysis
Below Book Valuation: The market values Renalytix AI plc's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Renalytix AI plc's assets decreased by 23.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Renalytix AI plc (2012–2025)
The table below shows the annual total assets of Renalytix AI plc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | GBX6.10 Million ≈ $742.19 |
-23.48% |
| 2024-06-30 | GBX7.97 Million ≈ $969.96 |
-99.99% |
| 2023-12-31 | GBX75.27 Billion ≈ $9.16 Million |
+178606.94% |
| 2023-06-30 | GBX42.12 Million ≈ $5.12K |
-33.42% |
| 2022-06-30 | GBX63.26 Million ≈ $7.70K |
-38.33% |
| 2021-06-30 | GBX102.58 Million ≈ $12.48K |
+148.38% |
| 2020-06-30 | GBX41.30 Million ≈ $5.02K |
+42.79% |
| 2019-06-30 | GBX28.92 Million ≈ $3.52K |
+50975.48% |
| 2018-06-30 | GBX56.63K ≈ $6.89 |
-100.00% |
| 2016-12-31 | GBX59.39 Billion ≈ $7.23 Million |
+4.57% |
| 2015-12-31 | GBX56.80 Billion ≈ $6.91 Million |
-2.29% |
| 2014-12-31 | GBX58.13 Billion ≈ $7.07 Million |
-7.25% |
| 2013-12-31 | GBX62.68 Billion ≈ $7.63 Million |
+2.92% |
| 2012-12-31 | GBX60.90 Billion ≈ $7.41 Million |
-- |
About Renalytix AI plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more